The Effects of Bindarit in Diabetic Nephropathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-03-31

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether bindarit is effective to reduce albuminuria, compared to placebo, in nephropathic patients treated with irbesartan, as a background therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria

NCT00320879

Type 2 Diabetes Microalbuminuria

COMPLETED PHASE4

A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril

NCT01398267

Diabetes Mellitus Type 2

COMPLETED PHASE1

This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)

NCT03165227

Diabetic Nephropathies

COMPLETED PHASE1

Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy

NCT06068439

Diabetic Nephropathy Type 2

NOT_YET_RECRUITING PHASE2/PHASE3

Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering Treatment

NCT01035320

Diabetes Mellitus Impaired Renal Function

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a pilot phase II, double-blind, multicentre, randomized, placebo-controlled, parallel groups study in patients with DN undergoing irbesartan therapy.

According to screening urinary albumin excretion, at baseline and before randomization, all patients will be categorized into 2 strata:

Stratum 1: microalbuminuria (20 to 200 μg/min, in at least 2 of 3 consecutive overnight urine samples collected at the screening) Stratum 2: macroalbuminuria (\>200 μg/min, in at least 2 of 3 consecutive overnight urine samples collected at the screening).

Within each stratum, patients will be randomly allocated on a 1:1 basis to the 2 treatment arms (after one month induction period):

* bindarit 600MG twice a day
* placebo All patients will be treated with irbesartan 300 mg/day as background therapy. After 12 months of treatment albuminuria will be evaluated as primary endopoint.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Nephropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bindarit

Patients treated with bindarit 2x300 mg bid plus irbesartan 2x150 mg once a day for 12 weeks

Group Type EXPERIMENTAL

Bindarit

Intervention Type DRUG

dosage form:tablet dosage:2x300 mg frequency:b.i.d duration:12 weeks

Placebo

patients treated with placebo 2 tablets bid plus irbesartan 2x150 mg once a day for 12 weeks

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

dosage form: tablet dosage: n.a. frequency: 2xplacebo b.i.d duration:12 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bindarit

dosage form:tablet dosage:2x300 mg frequency:b.i.d duration:12 weeks

Intervention Type DRUG

Placebo

dosage form: tablet dosage: n.a. frequency: 2xplacebo b.i.d duration:12 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AF2838

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* male and female patients with no limitation of race, aged 30 to 70 years;
* Type 2 diabetes defined as: \> 30 years of age at diagnosis; insulin not required within 6 months of initial diagnosis; no history of diabetic ketoacidosis; currently treated with diet, oral hypoglycemics or insulin \[Brenner 2000\];
* microalbuminuria defined as urinary albumin excretion, 20 to 200 µg/min in at least 2 of 3 overnight urine samples or macroalbuminuria defined as urinary albumin excretion, \> 200 µg/min in at least 2 of 3 overnight urine samples, confirmed in the baseline collection; should baseline albuminuria data not to be available, the patient may be conditionally treated;
* glycosylated haemoglobin (Hb A1c) \<12% at Screening \[Brenner 2000\];
* serum creatinine ≤ 3 mg/dL at Screening;
* normotensive patients or hypertensive patients on stable antihypertensive therapy over the last 3 months and without specific contraindications to angiotensin antagonist therapy;
* female patients of childbearing potential required to have a negative pregnancy test and use an approved birth control method;
* patients legally able to give written informed consent to the trial (signed and dated by the patient).

Exclusion Criteria

Patients cannot enter the trial under the following circumstances:

* patients hypersensitive or allergic to ARBs or bindarit or its components, or with a positive history for drug allergy;
* Type 1 diabetes \[Brenner 2000\];
* history of non diabetic renal disease, including renal artery stenosis \[Brenner 2000\];
* history of heart failure before enrolment \[Brenner 2000\];
* acute myocardial infarction, coronary artery bypass grafting within the past one month \[Brenner 2000\];
* cerebral vascular accident or coronary angioplasty within the past six months month \[Brenner 2000\];
* Transient Ischemic Attacks (TIA) in the past 12 months \[Brenner 2000\];
* primary aldosteronism or pheocromocytoma \[Brenner 2000\];
* severe uncontrolled hypertension (sitting diastolic blood pressure \> 115 and/or sitting systolic blood pressure\> 220 mm Hg) in the previous 6 months;
* chronic use of corticosteroids, non-steroidal anti-inflammatory drugs, immunosuppressive drugs, MAO inhibitors;
* patients under the influence of alcohol or narcotics;
* patients treated with experimental drugs in the previous 4 weeks.

Minimum Eligible Age

30 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No